Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (NASDAQ: LFCR) will report financial results for its second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
Senior management will host a webcast at 8:00 a.m. Eastern Time, accessible live and on-demand for 30 days via the Investor Events & Presentations page on the company’s website.
Lifecore Biomedical (NASDAQ: LFCR) announced three new customer agreements that expand its pipeline of early- and late-stage CDMO programs across multiple therapeutic and technology areas. All three programs are additive to Lifecore’s high-value pipeline and are expected by the company to contribute to revenue in 2028.
One agreement is a new late-stage regenerative medicine program under which Lifecore will provide technology transfer, engineering support, GMP readiness, and PPQ services, creating near-term development revenue and potential long-term commercial manufacturing. Two additional early-stage agreements with new customers, including a global medical technology company, focus on formulation optimization and development for novel medical technologies.
Lifecore Biomedical (NASDAQ: LFCR) granted an inducement restricted stock unit (RSU) award covering 3,500 shares of common stock on July 13, 2026 under its Equity Inducement Plan. The award was made to a newly hired employee as a material inducement to join the company and was approved by the compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Lifecore Biomedical (NASDAQ: LFCR) signed a new agreement with a global pharmaceutical company to provide tech transfer and commercial manufacturing services for an injectable suspension product treating neurological disorders.
This becomes Lifecore’s seventh late-stage program agreement in seven months, underscoring growing demand for its high-viscosity and complex drug manufacturing capabilities in the U.S.
Lifecore Biomedical (NASDAQ:LFCR) signed a manufacturing services agreement with a leading ophthalmic disease management company for a next-generation injectable ophthalmic product.
The deal covers process development and tech transfer from vials to pre-filled syringes, adds a sixth late-stage program in seven months, and supports anticipated commercial manufacturing upon regulatory approval.
Lifecore Biomedical (NASDAQ: LFCR) will participate in the William Blair 46th Annual Growth Stock Conference in Chicago. The event runs from June 2-4, 2026 at the Loews Chicago Hotel.
CEO Paul Josephs and CFO Ryan Lake will attend and hold investor meetings.
Lifecore Biomedical (NASDAQ: LFCR) reported Q1 2026 results and reaffirmed full-year guidance. Revenues were $23.2M (-34% YoY), gross margin 19.2%, adjusted EBITDA $1.0M, and net loss $15.0M (loss per share $0.43). Liquidity was approximately $38.1M. Company expects 2026 revenue of $120–125M and Adjusted EBITDA of $20.5–25M. Signed three new commercial site transfer programs and completed a January ERP launch to improve controls and costs.
Lifecore Biomedical (NASDAQ: LFCR) will report first-quarter 2026 financial results for the period ended March 31, 2026, on Wednesday, May 6, 2026 before market open. Lifecore management will host a live webcast at 8:00 a.m. Eastern to discuss results. An archived webcast will be available on the company's Investor Events & Presentations page for 30 days.
Lifecore (NASDAQ: LFCR) granted a restricted stock unit award for 5,000 shares as an inducement to a newly hired employee, effective April 20, 2026. The award was approved by the compensation committee under the company’s Equity Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The RSUs vest and will be settled on the third anniversary of the grant date, subject to continued employment, and are governed by an award agreement and the Inducement Plan.
Lifecore Biomedical (NASDAQ: LFCR) will participate at the 12th Annual American Biomanufacturing Summit on April 14-15, 2026 in San Francisco. Lifecore will discuss process development and manufacturing services for injectable programs and staff will be available at Booth 41.
Investors and partners may request meetings via cdmo@lifecore.com.